非小细胞肺癌PD-L1免疫组化检测多中心一致性研究
该多中心研究在7个中心对41例NSCLC手术标本同时使用5种抗PD-L1抗体进行免疫组化染色,比较标准化检测与实验室自建检测的一致性。结果显示28-8、22C3和SP263在肿瘤细胞染色上高度一致,SP263跨平台一致性最高;部分LDT与参考检测一致,但需谨慎验证。
要点
- 28-8、22C3和SP263三种 assay 在肿瘤细胞染色上高度一致。
- SP263在所有平台间一致性最高。
- 部分LDT与参考检测一致,但需进一步验证。
核心结论
- 28-8、22C3和SP263在7个中心间对肿瘤细胞染色具有接近的分析性能。
研究设计与样本
- 多中心研究,在7个中心对41例NSCLC手术标本进行PD-L1免疫组化染色,使用5种抗PD-L1抗体(28-8、22C3、E1L3N、SP142、SP263),共35种染色方案,由7名胸科病理医生评估。
主要发现
- 28-8、22C3和SP263在Dako或Ventana平台上对肿瘤细胞染色高度一致。
- 7个中心在Dako、Ventana和Leica平台上开发的27种LDT中,14种(51.8%)与参考检测对肿瘤细胞染色显示相似一致性。
- SP263克隆在所有平台上达到最高一致性。
- 使用四分类量表时,免疫细胞染色的一致性较低。
关键数值与推荐
- 肿瘤细胞表达阈值采用1%和50%,免疫细胞表达阈值采用1%、5%和10%进行统计分析。
临床怎么用
- 28-8、22C3和SP263可用于NSCLC肿瘤细胞PD-L1检测且跨平台一致性较好。
- LDT使用前需谨慎验证,部分LDT与参考检测一致性相似。
局限性
- LDT需进一步验证以提供使用建议。
- 免疫细胞染色一致性较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various programed death ligand 1 (PD-L1) immunohistochemistry (IHC) assays have been developed and used in clinical trials in association with different drugs. In order to harmonize and make PD-L1 testing in non-small-cell lung cancer (NSCLC) widely available, we conducted a multicenter study comparing PD-L1 standardized assays and laboratory-developed tests (LDTs). METHODS: IHC with five anti-PD-L1 monoclonal antibodies (28-8, 22C3, E1L3N, SP142 and SP263) was performed concomitantly on 41 NSCLC surgical specimens in 7 centers using Dako Autostainer Link 48 (3 centers), Leica Bond (2 centers) or Ventana BenchMark Ultra (2 centers) platforms. For each matching platform, 22C3, 28-8 and SP263 assays were performed. For nonmatching platforms and other antibodies, LDTs were developed in each center. A total of 35 stainings were performed for each case across different platforms and antibodies. PD-L1 staining was assessed in tumor cells and immune cells by seven trained thoracic pathologists. For statistical analysis, 1%, 50% and 1%, 5%, 10% expression thresholds were used for tumor cells and immune cells, respectively. RESULTS: 28-8, 22C3 and SP263 assays were highly concordant for tumor cells staining across the five Dako or Ventana platforms. Among 27 LDTs developed in 7 centers on Dako, Ventana and Leica platforms, 14 (51.8%) demonstrated similar concordance when compared with reference assays for tumor cell staining. Clone SP263 achieved the highest concordance rate across all platforms. Lower concordance was observed for immune cells staining when using a four categories scale. CONCLUSION: 28-8, 22C3 and SP263 assays had close analytical performance for tumor cell staining across seven centers. Some LDTs on Dako, Ventana and Leica platforms achieved similar concordance, but caution is warranted for their validation. These LDTs will be further validated in order to provide recommendations for the use of assays and LDT for PD-L1 testing in NSCLC.
引用
- Adam J, Le Stang N, Rouquette I, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018. PMID: 29351573. doi:10.1093/annonc/mdy014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。